The markets for solid tumors are much larger than the markets for leukemias and lymphomas, especially B-cell cancers. Therefore, we feel that the scope of opportunities for our CAR- T therapy is very large should we demonstrate efficacy in solid tumors. Our first indication will be ovarian cancer, followed by other tumor types.

Ovarian cancer is the sixth most common cancer in the world, and one of the most aggressive reproductive cancers among women. Most ovarian cancers are diagnosed at late stages (stage 3 or 4) due to the typical absence of symptoms and lack of screening approaches. Late stage diagnosis results in relatively high risks of recurrence and often poor prognosis. While the five-year survival rate for stage 1 ovarian cancer is over 80%, the corresponding survival rate for Stage 4 cancer is 20%.

Worldwide, over 200,000 cases of ovarian cancer are diagnosed annually.